Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01645059
Other study ID # ACI-CMM-2010-01
Secondary ID
Status Completed
Phase N/A
First received July 13, 2012
Last updated November 20, 2013
Start date July 2011
Est. completion date March 2013

Study information

Verified date November 2013
Source Asociación Cacereña para la Investigación y el Desarrollo en Oncología Médica
Contact n/a
Is FDA regulated No
Health authority Spain: Agencia Española de Medicamentos y Productos Sanitarios
Study type Observational

Clinical Trial Summary

This is an observational, cross-sectional study that the main objective is to describe the patient clinical profile that begins with disseminated Her 2+ Breast Cancer or develops a metastasis after or during the adjuvant treatment.


Recruitment information / eligibility

Status Completed
Enrollment 129
Est. completion date March 2013
Est. primary completion date March 2013
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Women with 18 years or over

- Patients with disseminated breast cancer histologically or cytological confirmed, who begins with Her 2+ metastatic breast cancer or develops a metastasis after or during the adjuvant therapy

- Patients treated in first line treatment in metastatic disease.

- Patients who have positive Her 2 receptor test

- Patients who have given their written informed consent

Exclusion Criteria:

- Patients who are participating in other studies

Study Design

Observational Model: Cohort, Time Perspective: Cross-Sectional


Related Conditions & MeSH terms


Locations

Country Name City State
Spain Hospital de Alcañiz Alcañiz Teruel
Spain Hospital de Torrecárdenas Almería
Spain Hospital Infanta Cristina de Badajoz Badajoz
Spain ICO Badalona Badalona Barcelona
Spain Clínica Corachan Barcelona
Spain Hospital San Pedro Alcántara Cáceres
Spain Complejo Hospitalario Ciudad Real Ciudad Real
Spain Hospital de Denia Denia Alicante
Spain Hospital don Benito Don Benito Badajoz
Spain Hospital General de Elda Elda Alicante
Spain Hospital de Galdakao Galdakao Vizcaya
Spain Hospital de Getafe Getafe Madrid
Spain Hospital de Cabueñes Gijón Asturias
Spain Hospital General de l'Hospitalet Hospitalet de Llobregat Barcelona
Spain Hospital de Jerez Jerez de la Frontera Cádiz
Spain Hospital Universitario de Canarias La Laguna Tenerife
Spain Hospital Severo Ochoa Leganés Madrid
Spain Hospital de León León
Spain Hospital Universitario Arnau de Vilanova Lleida
Spain Hospital de Llerena Llerena Badajoz
Spain Hospital Lucus Augusti Lugo
Spain Hospital La Princesa Madrid
Spain Hospital de Mérida Mérida Badajoz
Spain Hospital de Móstoles Móstoles Madrid
Spain Hospital Morales Messeguer Murcia
Spain Hospital Son Llàtzer Palma de Mallorca Islas Baleares
Spain Hospital Virgen del Puerto Plasencia Cáceres
Spain Hospital Quirón Pozuelo de Alarcón Madrid
Spain Hospital Universitario de la Candelaria Santa Cruz de Tenerife Tenerife
Spain Hospital General de Segovia Segovia
Spain Hospital Virgen de la Macarena Sevilla
Spain Hospital Reina Sofía de Tudela Tudela Navarra
Spain Hospital Dr.Peset Valencia
Spain Hospital General Universitario de Valencia Valencia
Spain Hospital Clínico de Valladolid Valladolid
Spain Hospital Universitario Rio Hortega Valladolid
Spain Hospital do Meixoeiro Vigo Pontevedra
Spain Hospital de Txagorritxu Vitoria Álava
Spain Hospital de Zamora Zamora

Sponsors (1)

Lead Sponsor Collaborator
Asociación Cacereña para la Investigación y el Desarrollo en Oncología Médica

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Patient Clinical Profile (General Clinical Data and Breast Cancer Characteristics) General clinical data: age, weigh, height, Perfomance Status (ECOG Eastern Cooperative Oncology Group, runs from 0 to 5, with 0 denoting perfect health and 5 death), Breast cancer characteristics: familiar history of breast cancer, initial diagnostic (localized or disseminated), age at diagnostic, TNM (tumor node metástasis), tumor size, node involvement, primary tumor surgery, HER2 overexpression, histological Classification (grades I, II and III,determines the urgency and aggressiveness of treatment, as the higher grades do tend to correspond to poorer survival rates and prognosis), time from the primary breast cancer to distant relapse, description and localization of metastasis 1 day (there is no follow-up, it is a cross-sectional study) No
Secondary Adjuvant Treatment in Primary Breast Cancer: Chemotherapy (Treatment With TAC-Docetaxel, Adriamicine and Cyclophosphamide), Hormonal Therapy Anti-HER Biological Therapy one day (there is no follow-up, it is a cross-sectional study) No
Secondary The Pattern of Treatment in Metastatic Breast Cancer: Chemotherapy, Hormonal Therapy Anti-HER Biological Therapy one day (there is no follow-up, it si a cross-sectional study) No
Secondary Adjuvant Treatment and Age Adjuvant treatment and clinical profile (age)
The patients analysed in this outcome are patients initially diagnosed with localized breast cáncer (N=66)
one day (there is no follow-up, it is a cross-sectional study) No
Secondary Adjuvant Treatment-Physical Activity Adjuvant treatment and clinical profile (Physical activity)
The patients analysed in this outcome are patients initially diagnosed with localized breast cáncer (N=66)
one day (there is no follow-up, it is a cross-sectional study) No
Secondary Adjuvant Treatment-Node Affectation Adjuvant treatment and clinical profile (Node affectation)
The patients analysed in this outcome are patients initially diagnosed with localized breast cáncer (N=66)
one day (there is no follow-up, it is a cross-sectional study) No
Secondary Disseminated Breast Cancer Treatment-Age Analyse disseminated Breast Cancer treatment and clinical profile (age) one day (there is no follow-up, it is a cross-sectional study) No
Secondary Disseminated Breast Cancer Treatment-physical Activity Analyse disseminated Breast Cancer treatment and clinical profile (physical activity) one day (there is no follow-up, it is a cross-sectional study) No
Secondary Disseminated Breast Cancer Treatment-Smoking Analyse disseminated Breast Cancer treatment and clinical profile (Smoking) one day (there is no follow-up, it is a cross-sectional study) No